SCHEMBL4870764

SCHEMBL4870764

CCN(CCCNC(=O)N1CCCCc2cc(F)ccc21)c1ccc(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.52
MAPT P10636 3/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.45
KDM4E B2RXH2 1/20 0.45
GAA P10253 1/20 0.45
HTT P42858 1/20 0.45
GFER P55789 1/20 0.45
AVPR2 P30518 1/20 0.43
KMT2A Q03164 2/20 0.42
HDAC1 Q13547 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
NOTUM Q6P988 1/20 0.41
PDK1 Q15118 1/20 0.39
PDK2 Q15119 1/20 0.39
PDK3 Q15120 1/20 0.39
PDK4 Q16654 1/20 0.39
ADRB2 P07550 2/20 0.39
ADRB1 P08588 2/20 0.39
ADRB3 P13945 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4868380 0.94 LMNA (0.54) LMNAMAPTALDH1A1HPGDKDM4E
SCHEMBL4869509 0.90 AVPR2 (0.52) LMNAMAPTKDM4EAVPR2KMT2A
SCHEMBL4870682 0.85 AVPR2 (0.51) LMNAMAPTALDH1A1HPGDKDM4E
SCHEMBL4870765 0.84 AVPR2 (0.54) LMNAMAPTKDM4EGFERAVPR2
SCHEMBL4860776 0.83 LMNA (0.43) LMNAMAPTALDH1A1HPGDKDM4E
SCHEMBL4863777 0.82 KMT2A (0.55) LMNAMAPTAVPR2KMT2AMEN1
SCHEMBL4869537 0.81 HDAC1 (0.47) LMNAKMT2AHDAC1HDAC6NOTUM
SCHEMBL4871198 0.80 LMNA (0.45) LMNAMAPTKDM4EAVPR2HDAC1
SCHEMBL4868271 0.79 KMT2A (0.52) LMNAMAPTGFERAVPR2KMT2A
SCHEMBL4872578 0.79 AVPR2 (0.52) LMNAMAPTGFERAVPR2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 LMNA 2162/4885MAPT 3398/4885ALDH1A1 3990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.